Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma

doi:10.3748/wjg.v18.i42.6005

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 42

This Article

(0)

(11686)

(41)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Editorial

World J Gastroenterol. Nov 14, 2012; 18(42): 6005-6017
Published online Nov 14, 2012. doi: 10.3748/wjg.v18.i42.6005

Table 1 Molecular targeted agents for hepatocellular carcinoma: Targets and development status

Agents	Targets (angiogenesis)			Targets (proliferation)				Positioning	Development status
Agents	VEGFR	PDGFR	FGF	EGFR	Raf	mTOR	TRAIL-R2	DR5	Development status
Sorafenib	●	●			●			1st line	Approved
Sunitinib	●	●						1st line	PIII terminated
E7080	●	●	●					1st/2nd line	PII ongoing
Tigatuzumab (CS1008)							●	1st line (sorafenib combination)	PI/II ongoing
Linifanib (ABT-869)	●	●						1st line	PIII ongoing
Brivanib		●			●			1st line, 2nd line, TACE adjuvant	PIII ongoing
TSU-68		●	●					TACE combination	PIII ongoing
Ramucirumab		●						2nd line	PIII ongoing
Everolimus (RAD001)						●		2nd line	PIII ongoing
Axitinib		●	●					2nd line	PIII ongoing

VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; FGF: Fibroblast growth factor; EGFR: Epidermal growth factor receptor; mTOR: Mammalian target of rapamycin; TACE: Transarterial chemoembolization.

Full Size Table

Citation: Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017
URL: https://www.wjgnet.com/1007-9327/full/v18/i42/6005.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i42.6005

Kudo M. Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol 2012; 18(42): 6005-6017 [PMID: 23155330 DOI: 10.3748/wjg.v18.i42.6005]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.